

1 **Evaluation of a novel respiratory virus inactivating buffer for parallel RT-qPCR and quick antigen**  
2 **testing**

3 Sigrid DEPREZ<sup>1</sup>, Sophia STEYAERT<sup>1</sup>, Mikhail CLAEYS<sup>2</sup>, Ludwig VERHASSELT<sup>2</sup>, Jo VANDESOMPELE<sup>2</sup>

4 <sup>1</sup> Department of Laboratory Medicine, General Hospital Maria Middelaes, Buitenring-Sint-Denijs 30, 9000  
5 Ghent, Belgium

6 <sup>2</sup> InActiv Blue, Industriepark Oost 2A, 8730 Beernem, Belgium

7 **ABSTRACT**

8 Since the COVID-19 pandemic, many hospitals implemented a dual testing procedure for SARS-CoV-2  
9 to assess the infection risk of an admitted patient. To allow for a short turn-around time, rapid antigen  
10 (Ag) testing via lateral flow tests (LFT) is combined with nucleic acid amplification testing (NAAT),  
11 requiring two nasopharyngeal swab collections. In this study, a novel, universal pathogen inactivation  
12 buffer (DNA/RNA Defend Pro (DRDP)) was evaluated for SARS-CoV-2 inactivation and simultaneous Ag  
13 and DNA/RNA stabilization.

14 In an emergency department setting of a General Hospital in Ghent (Belgium), patients were tested  
15 for SARS-CoV-2, whereby a LFT for Ag detection (Abbott Panbio COVID-19 Ag Rapid Test) was  
16 performed in combination with sample collection for NAAT (Abbott Alinity m). Left-over buffers from  
17 LFT were diluted in DRDP to evaluate LFT and NAAT results after dilution. Thirty-six patients were  
18 included in the data analysis.

19 Twenty-three diagnostic LFT results were available in the laboratory information system of which all  
20 corresponded with results after dilution with DRDP. When correlating NAAT results, seven out of eight  
21 positive test results were in agreement, compared to twenty-three out of twenty-five negative results.  
22 For thirty-four out of thirty-six samples, LFT and NAAT after dilution with DRDP yielded the same  
23 conclusion. Additionally, RNA stability in DRDP was demonstrated when stored for three days at room  
24 temperature. At the extreme, a sample stored in the DRDP buffer for 53 days at room temperature  
25 was still very positive (Cq 21.95).

26 We demonstrated that, for the first time, a novel collection buffer could inactivate a pathogen (SARS-  
27 CoV-2) while also preserving antigen (for rapid antigen testing) and RNA (for molecular testing). This  
28 novel buffer holds promise for a single specimen to be used for both antigen and molecular testing in  
29 a safe working environment.

30 **Keywords:** inactivating buffer; SARS-CoV-2; Influenza; nucleic acid amplification test; rapid antigen  
31 testing

32

## 33 1. INTRODUCTION

34 In 2019, a new coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged  
35 from Wuhan (China) causing a worldwide pandemic <sup>1</sup>. SARS-CoV-2 causes severe disease to human  
36 known as coronavirus disease 2019 (COVID-19). This pandemic illustrated the importance of  
37 diagnostic tests to identify SARS-CoV-2 infections and thereby allowing to slow down the spread of  
38 the virus <sup>2</sup>. The need for diagnostic tests led to the fast development of testing methods including  
39 rapid antigen (Ag) testing based on lateral flow tests (LFT) and nucleic acid amplification testing (NAAT)  
40 using polymerase chain reaction (PCR)-based tests <sup>3</sup>. From a biosafety perspective, virus inactivating  
41 protocols were needed to permit safe transportation of diagnostic sampling material for NAAT in  
42 dedicated laboratories. Inactivating buffers have recently been developed for that purpose, allowing  
43 for safe NAAT, simultaneously inactivating and preserving clinical samples. An example of such a  
44 pathogen inactivating, RNA/DNA stabilizing transport medium for in vitro diagnostic testing using PCR  
45 methods is the InActiv Blue medium (InActiv Blue, Beernem, Belgium) <sup>4-9</sup>.

46 In healthcare institutions in Belgium and abroad, two-step protocols have been introduced during  
47 different SARS-CoV-2 waves to allow for screening and confirmation of infected individuals. At the  
48 Maria Middelaers General Hospital (Ghent, Belgium), an initial screening at the emergency  
49 department (ED) is performed using a rapid Ag test, allowing for a very short turn-around time (TAT)  
50 of only 15 minutes between sampling and result. The rapid Ag test result is then followed by  
51 confirmation by NAAT. Such a two-step protocol allows for immediate action and isolation in case of  
52 a positive test, while gaining insight in the viral load based on the NAAT result. However, a  
53 disadvantage is the need for sampling of two separate nasopharyngeal swabs because of the absence  
54 of a universal medium. A major drawback of most commercially available, pathogen inactivating  
55 transportation media, is their limited Ag stabilizing effect while being suited for NAAT testing. Vice  
56 versa, Ag testing buffers mostly do not have RNA/DNA stabilizing properties, nor pathogen  
57 inactivation properties. Currently, at AZ Maria Middelaers, nasopharyngeal swabs are collected in  
58 InActiv Blue (InActiv Blue, Beernem, Belgium) inactivation medium allowing safe sample handling and  
59 transportation <sup>4</sup>.

60 Through the development of more universal media, stabilizing RNA while also keeping Ag intact,  
61 combined testing on one sample would become possible. After performing NAAT, also other Ag tests  
62 for respiratory pathogens could be conducted. This is a potential benefit compared to classic,  
63 commercial inactivation media. InActiv Blue recently developed such a “universal medium”, the  
64 DNA/RNA Defend Pro medium (DRDP) for combined Ag and PCR testing <sup>10</sup>.

65 A similar medium has been developed by RNAssist, “virusPHIX” and “virusPHIX-P9” (Rapid Labs, Essex,  
66 England) in 2020 <sup>11</sup>. The VirusPHIX medium has been developed for virus inactivation and RNA  
67 stabilization, offering safe collection and transport of SARS-CoV-2 clinical swab and saliva samples to  
68 clinical laboratories for both COVID-19 LFT and PCR testing. The medium has been developed for  
69 research use only. Nevertheless, no scientific literature has been published demonstrating the  
70 effectiveness of the medium.


71 The primary objective of this study was to evaluate the performance of the DRDP medium for SARS-  
72 CoV-2 rapid Ag testing as well as its suitability for SARS-CoV-2 NAAT testing compared to the currently  
73 used protocols for SARS-CoV-2 Ag and NAAT testing at the clinical laboratory of General Hospital AZ  
74 Maria Middelaers. Additionally, for samples positive for other respiratory viruses (Influenza A and B,  
75 and respiratory syncytial virus (RSV)), preliminary data was collected on the performance of DRDP for  
76 NAAT testing in comparison with InActiv Blue (current diagnostic medium).

## 77 2. MATERIALS AND METHODS

### 78 2.1. Sample collection and analysis

79 Left-over buffers of LFT for SARS-CoV-2 antigen (Ag) testing, sampled from patients admitted at the  
80 ED of the Maria Middelaes General Hospital (Ghent, Belgium) over a period from January 2023 until  
81 April 2023, were collected. Initially, an inclusion target of 50 patients was set. This study was approved  
82 by the Ethics Committee of Maria Middelaes General Hospital (EC MMS.2023.045).

83 As part of the standard clinical care in the hospital, two distinct nasopharyngeal swabs were sampled  
84 of admitted patients at the ED to determine the SARS-CoV-2 infection risk, as depicted in [Figure 1](#).



85

86 *Figure 1. Graphical representation of sample collection of a patient at the emergency department and further processing in*  
87 *the laboratory followed by dilution in DNA/RNA Defend Pro medium (DRDP).*

88 Using a first nasopharyngeal swab (red swab depicted in [Figure 1](#)), a LFT to detect SARS-CoV-2 Ag was  
89 performed at the ED by trained medical personal, using Abbott Panbio COVID-19 Ag Rapid Test Devices  
90 (Abbott, Chicago, Illinois, United States) in accordance with the product leaflet<sup>12</sup>. Additionally, a  
91 second swab was collected (blue swab depicted in [Figure 1](#)) in virus inactivating medium (InActiv Blue,  
92 Beernem, Belgium) for safe transportation to the laboratory for NAAT for SARS-CoV-2. As outlined  
93 above, InActiv Blue (IAB) is a virus inactivation and RNA-stabilizing lysis buffer<sup>4</sup>. Upon arrival at the  
94 microbiology laboratory, NAAT was performed by real time reverse transcriptase polymerase chain  
95 reaction (RT-PCR), conducted on an Abbott Alinity m platform (Abbott, Chicago, Illinois, United States).  
96 Multiplex Resp-4-Plex assays were used to simultaneously detect SARS-CoV-2 virus, Influenza A and B,  
97 and Respiratory Syncytial Virus (RSV) given the flu season at the time of conducting the study<sup>13</sup>.

98 Within the framework of this study, left-over sample buffer in test tubes and test cartridges of Panbio  
99 COVID-19 Ag Rapid Test Devices (test number 2 at [Figure 1](#)) were transported in a biohazard safety  
100 bag to the clinical laboratory at the Maria Middelaes General Hospital using pneumatic transportation  
101 tubes. Upon arrival at the laboratory, buffer tubes and test cartridges were pseudonymized with a  
102 patient study code (COV-xx). A photographic image was taken of the original test cartridges when  
103 available (test number 2 in [Figure 1](#)) for visual comparison with the test cartridge result after sample  
104 buffer dilution in DRDP (test number 2A in [Figure 1](#)), as outlined below.

105 Following pseudonymization of the buffer tubes and cartridges, left-over samples were diluted in  
106 DRDP. A minimal volume of 50  $\mu\text{L}$  from the left-over sample was diluted to a total volume of 350  $\mu\text{L}$   
107 with DRDP medium in an Eppendorf tube. This was followed by a vortexing and homogenization step.  
108 From the Eppendorf tube, 250  $\mu\text{L}$  was subsequently transferred to a new test tube (Abbott rapid  
109 antigen test kit). A fixed volume of base (1 M NaOH, 6.8% v/v, equi) was added to the new test tube  
110 to bring the pH to  $> 6.5$  (i.e. 16-17  $\mu\text{L}$ ). An acidic pH would precipitate the colloidal gold in the Ag test  
111 device during analysis. After vortexing the tube, a second LFT (Panbio COVID-19 Ag rapid test) was  
112 performed. The analysis was performed as prescribed on the leaflet. No additional nasopharyngeal  
113 sampling was required, since the buffer tube was filled with sample diluted in DRDP (see above). Five  
114 drops of sample were dispensed vertically into the specimen well on the cartridge device. After 15  
115 minutes (not more than 20 minutes) the results were read from the cartridge. A photographic image  
116 was taken when the results were interpreted for visual comparison with the original (diagnostic) test  
117 cartridge result.

118 Secondly, the remaining 100  $\mu\text{L}$  in the Eppendorf tube was transferred to a tube for PCR-analysis, as  
119 depicted in [Figure 1](#), test 2B. The left-over buffer was further diluted with DRDP to a total volume of  
120 1250  $\mu\text{L}$  (1500  $\mu\text{L}$  for some positive samples because of a smaller left-over volume for reanalysis).  
121 Here, no 6.8% (v/v) basic solution was added for performance of NAAT.

122 Samples in DRDP that tested positive for SARS-CoV-2 with NAAT (PCR tubes), were stored for 3 days  
123 at room temperature for reanalysis to assess sample stability in DRDP.

## 124 **2.2. Method comparison**

125 LFT results for SARS-CoV-2 were interpreted as 'negative', 'positive' or 'invalid' in agreement with the  
126 product leaflet<sup>12</sup>. Rapid Ag test results as part of diagnostic care ([Figure 1](#), test 2) were compared with  
127 test results after dilution in DRDP ([Figure 1](#), test 2A). Agreement between paired samples was  
128 evaluated.

129 Using Abbott Alinity m NAAT (Resp-4-Plex), Cq values were obtained for the detection of SARS-CoV-2,  
130 Influenza A, Influenza B, and RSV DNA/RNA. Based on the SARS-CoV-2 Cq value, samples were  
131 categorized as 'negative' (no detection), 'weak positive' ( $Cq > 24.82$ ), 'positive' ( $18.43 < Cq \leq 24.82$ ),  
132 'strong positive' ( $12.04 < Cq \leq 18.43$ ) and 'very strong positive' ( $Cq \leq 12.04$ ). Categorical NAAT results  
133 as part of diagnostic care ([Figure 1](#), test 1) were compared with NAAT results after dilution in DRDP  
134 ([Figure 1](#), test 2B). Importantly, paired NAAT results originate from different samplings, as visually  
135 indicated in [Figure 1](#). Besides the comparison of categorical results between paired NAAT samples,  
136 delta Cq values were calculated. Using delta Cq values ( $\Delta Cq$ ), the dilution factor in DRDP can be taken  
137 into account. Additionally, it allows us to compare the results across different samples.

138 For each sample, Cq values obtained as part of diagnostic care (sampled in InActiv Blue, IAB), were  
139 subtracted from Cq values obtained after dilution in DRDP to obtain a  $\Delta Cq$  value ( $\Delta Cq = Cq_{\text{DRDP}} - Cq_{\text{IAB}}$ ).  
140 After calculating  $\Delta Cq$  values for each sample, a mean and median  $\Delta Cq$  value for SARS-CoV-2  
141 for all samples was compared to the expected  $\Delta Cq$  based on sample dilution. For NAAT, samples were  
142 87.5 times diluted in DRDP ([Figure 1](#), test 2B) when considering a minimal left-over volume of 50  $\mu\text{L}$ .  
143 A theoretical  $\Delta Cq$  of 6.45 was thus expected ( $\Delta Cq_{\text{expected}} = \log_2(87.5)$ ). To allow for a more accurate  
144 estimation of expected  $\Delta Cq$ , left-over sample volumes were measured approximately and taken into  
145 account for calculation of expected  $\Delta Cq$ . Again, note that the original Cq and diluted Cq come from  
146 an independent swab.

147 Additionally,  $\Delta Cq$  values for SARS-CoV-2 were calculated for positive DRDP samples analyzed on day  
148 0 and day 3 ( $\Delta Cq_{\text{stability}} = Cq_{\text{DRDP day 3}} - Cq_{\text{DRDP day 0}}$ ), and mean and median  $\Delta Cq$  values were

149 determined. Here a  $\Delta Cq_{\text{expected}}$  of zero was expected, since no additional dilution was performed and  
150 RNA stability assumed.

151 Thirdly, LFT results in DRDP (**Figure 1**, test 2A) and DRDP SARS-CoV-2 NAAT results (**Figure 1**, test 2B)  
152 were compared qualitatively ('positive' or 'negative') to assess agreement between paired samples in  
153 DRDP, originating from the same sampling.

154 Finally, for samples positive for Influenza A, Influenza B, or RSV,  $\Delta Cq$  values were also determined and  
155 compared to the expected  $\Delta Cq$  ( $\Delta Cq_{\text{expected}} = \log_2(87.5) = 6.45$ ), as outlined above. Also here, to allow  
156 for a more accurate estimation of expected  $\Delta Cq$ , left-over sample volumes were measured  
157 approximately and taken into account for calculation of expected  $\Delta Cq$ . Also here, the original  $Cq$  and  
158 diluted  $Cq$  come from an independent swab.

159

160 **3. RESULTS**


161 **3.1. Lateral flow test results – SARS-CoV-2**

162 In total, 36 left-over samples were collected. For 23 out of 36 samples, LFT results were available in  
 163 the laboratory information system (LIS). Seven samples (on a total of 23) were reported positive,  
 164 sixteen as negative (**Table 1, “Panbio”**). For all seven positive samples, concordant positive results  
 165 were obtained after dilution in DRDP, as displayed in **Table 1, “DRDP”**. All sixteen negative samples  
 166 also tested negative after dilution. For one of the remaining 13 samples, for which a negative result  
 167 was mentioned in the electronic patient file, a weak positive result was obtained after dilution.  
 168 However, no official report was received by the laboratory (not included in **Table 1** since no LIS result  
 169 was reported). For the remaining twelve samples, although performed at the ED, no diagnostic LFT  
 170 result was reported.

171 *Table 1. Results LFT for SARS-CoV-2 (Diagnostic Panbio vs. after dilution in DRDP)*

	positive Panbio	negative Panbio	total
positive DRDP	7	0	7
negative DRDP	0	16	16
total	7	16	23

172  
 173 Additionally, intensities of LFT results were compared, as depicted in **Figure 2**. Although no  
 174 quantitative result can be deduced from a LFT, Ag-band intensities for SARS-CoV-2 correspond quite  
 175 well for diagnostic LFT versus LFT after dilution in DRDP. Overall, comparing Ag testing results before  
 176 (diagnostic test) and after dilution (in DRDP), all results were in agreement. The dilution in DRDP with  
 177 a median factor of 5.0 (range 1.9-9.3), did not significantly influence LFT results nor the test sensitivity  
 178 or specificity compared to the diagnostic LFT.



179  
 180 *Figure 2. Comparison of SARS-CoV-2 Ag detection intensities for six samples on diagnostic LFT vs. LFT after dilution in DRDP.*  
 181 *Numbers between brackets reflex sample numbers as indicated in Supplementary Data File 1.*

### 3.2. Nucleic acid amplification test results – SARS-CoV-2

182  
183 For three out of 36 samples, no NAAT results in IAB buffer were available in the LIS. For 8 samples, Cq  
184 values were obtained ranging from 11.28 to 23.31. No SARS-CoV-2 RNA was detected in 25 samples  
185 (Table 2). Using the left-over LFT samples, after dilution in DRDP, 7 of 8 NAAT positive samples tested  
186 positive with Cq values ranging from 14.70 to 33.23. One sample negativized after dilution of the LFT  
187 left-over buffer, although a diagnostic Cq value of 17.69 (categorized as strong positive) was obtained.  
188 Comparison with diagnostic LFT results (as outlined below) was used to clarify this discrepancy.  
189 Importantly, the diagnostic test results compared with NAAT results after dilution in DRDP originate  
190 from two different nasopharyngeal swab samplings.

191 When comparing categorical NAAT results, which are important for test interpretation and  
192 management in the hospital, for the 8 positive NAAT samples in IAB, results in DRDP differed for 6  
193 samples with not more than 1 category, for 1 sample with 2 categories (strong positive vs. weak  
194 positive), and 1 sample tested negative in DRDP.

195  $\Delta$  Cq values values between NAAT in IAB buffer (diagnostic PCR test) and in DRDP ranged from 1.33 to  
196 20.64, with a mean and median  $\Delta$  Cq of 5.77 and 3.28 for SARS-CoV-2. These values are in close  
197 agreement with  $\Delta$  Cq<sub>expected</sub> value of 5.64 (1/50 dilution) despite the fact that different samplings are  
198 compared.  $\Delta$  Cq<sub>expected</sub> was calculated based on the exact sample dilutions as the left-over sample  
199 volumes ranged from 40-200  $\mu$ L. Detailed calculations can be found in [Supplementary Data File 1](#). For  
200 two samples, no SARS-CoV-2 RNA was detected with the diagnostic test in IAB, and a positive result  
201 was obtained after dilution in DRDP. In both instances, a weak positive test result was obtained (Cq  
202 values of 38.26 and 37.47).

203 Additionally, NAAT (DRDP) results were compared when analysed on day 0 and day 3 after storage at  
204 room temperature. Categorical NAAT results differed maximally with 1 category between paired  
205 results. Absolute  $\Delta$  Cq values ranged from 0.38 to 1.29 with a mean and median  $\Delta$  Cq of 0.24 and 0.43,  
206 indicating no stability issues occurred when stored at room temperature. One sample was even stored  
207 for 53 days at room temperature for which a Cq value of 21.95 was obtained. Although no test result  
208 was available at day 0, the fact that still a 'positive' test result could be obtained indicates a good  
209 stabilization of viral RNA at room temperature for prolonged time. Similar stability results were  
210 obtained for saliva collected in DRDP (1.2 mL saliva in 2 mL DRDP), whereby delta Cq was < 1 when  
211 stored for 2 weeks at room temperature (data not shown)<sup>10</sup>.

212 *Table 2. Results molecular testing SARS-CoV-2 (diagnostic Abbott Alinity m vs. after dilution of LFT sample in DRDP)*

	positive InActiv Blue	negative InActiv Blue	total
positive DRDP	7	2	9
negative DRDP	1	23	24
total	8	25	33

213

### 3.3. Comparison of lateral flow and nucleic acid amplification test results – SARS-CoV-2

214 To assess the performance of DRDP for both LFT and NAAT for SARS-CoV-2, paired results after dilution  
215 of the same left-over sample in DRDP were compared. Nine Ag tests resulted positive for SARS-CoV-  
216 2. All paired PCR tests also tested positive (100% sensitivity).  
217  
218

219 Out of 27 negative DRDP Ag tests, 25 also tested negative with PCR. Two negative Ag DRDP tests scored  
220 weak positive using PCR testing for SARS-CoV-2 with Cq values of 37.47 and 26.59. For the sample with  
221 a Cq of 26.59, no officially reported Panbio Ag test result was available. However, because the test  
222 cartridge was sent to the lab, a negative result could be read. The diagnostic PCR test for this particular  
223 sample was also positive with a Cq value of 23.31. For the second discrepant sample, with a NAAT in  
224 DRDP Cq value of 37.47, both diagnostic LFT and NAAT tested negative. However, a Cq value of 37.47  
225 is close to the detection limit of the method.

226 *Table 3. Results molecular testing SARS-CoV-2 compared to LFT for SARS-CoV-2 after dilution in DRDP*

	positive LFT DRDP	negative LFT DRDP	total
positive NAAT DRDP	9	2	11
negative NAAT DRDP	0	25	25
total	9	27	36

227

### 228 **3.4. Influenza A, Influenza B, and RSV nucleic acid test results**

229 Since NAAT was performed using Abbott Alinity m RESP-4-PLEX, also Cq values for Influenza A and B,  
230 and RSV were obtained. Unfortunately, no rapid Ag test results were available for any of the  
231 aforementioned respiratory viruses. PCR results in IAB (diagnostic PCR test) and DRDP were compared.  
232 Five samples tested positive for Influenza A, one sample for Influenza B and none of the samples for  
233 RSV. For Influenza A, mean and median  $\Delta$  Cq values between PCR in IAB and DRDP were 7.12 and 5.25.  
234  $\Delta$  Cq was 2.28 for Influenza B. A  $\Delta$  Cq<sub>expected</sub> of 5.64 for Influenza A (average dilution of 1/50) and 5.87  
235 for Influenza B (average dilution of 1/58) was found taking into account left-over sample volumes for  
236 Influenza A or B. Detailed calculations can be found in [Supplementary Data File 1](#). As outlined above  
237 for SARS-CoV-2, this is in line with the dilution in DRDP that was performed. Overall, the diagnostic  
238 results were in agreement with DRDP diluted results for Influenza A and B.

239



#### 240 4. DISCUSSION

241 In an ideal scenario for evaluating a novel sample collection buffer, the swab is collected in the buffer  
242 itself. However, to minimize patient discomfort, leftover samples from routine rapid antigen testing  
243 were used. When comparing the diagnostic LFT results and the LFT results upon dilution in DRDP, we  
244 conclude that the use of DRDP universal buffer does not affect rapid antigen test performance since  
245 no discrepant results were obtained. Here, the results originated from the same pre-analytical matrix,  
246 simplifying data analysis.

247 In contrast, when comparing the diagnostic NAAT results and NAAT results after dilution in DRDP, a  
248 small number of conflicting data points were obtained. Pre-analytically, these results originate from  
249 different samplings (as depicted in [Figure 1](#)) and are therefore independent of each other,  
250 complicating interpretation. First, one sample tested strongly positive using the diagnostic NAAT test  
251 in IAB (Cq value of 17.69), while the in DRDP diluted counterpart tested negative. Since both the  
252 diagnostic LFT for SARS-CoV-2 and the LFT after dilution in DRDP tested negative, a likely explanation  
253 can be found in a poor sample quality of the nasopharyngeal swab for diagnostic LFT. Secondly, two  
254 samples tested weak positive with NAAT after dilution in DRDP, while the diagnostic NAAT was  
255 negative. For one sample with a Cq of 38.26, the diagnostic NAAT tested negative while both  
256 diagnostic LFT and DRDP diluted LFT tested positive. This indicates a good agreement between LFT  
257 and NAAT after DRDP dilution, while the discrepant result may stem from (1) the pre-analytical phase,  
258 or (2) due to the high Cq value (repetition of diagnostic NAAT test might have resulted in a weak  
259 positive result). The second sample had a Cq of 37.47 while diagnostic NAAT and LFT tested negative.  
260 Repetition of the NAAT in DRDP at day 3 also gave a weak positive result with a Cq of 36.18, confirming  
261 the weak positive result. Possibly, while diluting the sample, cross-contamination may have occurred.

262 Comparing LFT and NAAT results in DRDP, two samples tested negative with LFT, but positive with  
263 NAAT. The conflicting result for one sample could be attributed to contamination, as outlined above.  
264 For the second sample, an inherent higher sensitivity of NAAT for detection of SARS-CoV-2 likely  
265 explains the obtained result.

266 For some of the discrepant results, mainly when results originate from two different pre-analytical  
267 samples, human errors might have played a role. Especially since for molecular testing in DRDP a  
268 dilution of the rapid Ag buffer was used, which could explain some discrepancies observed in our  
269 dataset. Furthermore, samples were collected in a clinical setting, not in ideal lab circumstances, which  
270 resulted in some missing datapoints besides the possibility of human errors.

271 Since very few data is available for virusPHIX, another universal medium that is commercially available,  
272 no comparison was made on this end <sup>11</sup>.

273 A limitation of this study is the low number of positive samples included. Additionally, the  
274 performance of the buffer on the molecular analyses of other respiratory viruses was only preliminary  
275 tested since few positive samples for Influenza A (n = 5) and Influenza B (n = 1) were included. No  
276 positive samples for RSV were present in the data set. Unfortunately, no rapid Ag testing was  
277 diagnostically performed for Influenza A or B, or RSV at the laboratory of AZ Maria Middelaers.

#### 278 5. CONCLUSION

279 With the data collected in this study, we demonstrated that the DNA/RNA Defend Pro medium is a  
280 promising inactivating medium that allows for both reliable Ag testing and PCR analysis for SARS-CoV-  
281 2, but also influenza A and influenza B. Additionally, our limited stability results show that RNA is  
282 stabilized in DRDP buffer for at least 3 days at room temperature, probably longer. In the future,

283 studies collecting parallel nasal swabs in IAB and DRDP are needed to conclusively demonstrate the  
284 usability of DRDP in clinical practice.

## 285 **6. ACKNOWLEDGEMENTS**

286 The authors wish to acknowledge all laboratory staff of Maria Middelaes General Hospital that aided  
287 in the reception and processing of the left-over samples. In particular, S.D. would like to specially thank  
288 Lies Bouchier, head MLT microbiology, for the practical aid during the study. The ED nurses and  
289 doctors are acknowledged for the collection of left-over samples. DNA/RNA Defend Pro medium was  
290 provided by InActiv Blue. Figures were created with Biorender.com.

291

## 292 7. REFERENCE

293

- 294 1. World Health Organization (WHO). *WHO-convened global study of origins of SARS-CoV-2:*  
295 *China Part.* (2021).
- 296 2. Rosenthal, P. J. The importance of diagnostic testing during a viral pandemic: Early lessons from  
297 novel coronavirus disease (CoVID-19). *Am. J. Trop. Med. Hyg.* **102**, 915–916 (2020).
- 298 3. World Health Organization (WHO). *Diagnostic testing for SARS-CoV-2, Interim guidance.*  
299 (2020). doi:10.1016/S0025-7125(05)70348-5
- 300 4. InActiv Blue. Inactiv Blue buffer. (2023). Available at: [https://www.inactivblue.com/inactiv-](https://www.inactivblue.com/inactiv-blue-buffer/)  
301 [blue-buffer/](https://www.inactivblue.com/inactiv-blue-buffer/). (Accessed: 20th September 2023)
- 302 5. Jonckheere, I. *et al.* Equivalence of Saliva RT-qPCR Testing to Nasal-throat/Nasopharyngeal  
303 Swab Testing in the General Practitioner’s Setting to Detect SARS-CoV-2. *J. Pediatr. Perinatol.*  
304 *Child Heal.* **06**, 42–53 (2021).
- 305 6. De Meyer, J. *et al.* Evaluation of Saliva as a Matrix for RT-PCR Analysis and Two Rapid Antigen  
306 Tests for the Detection of SARS-CoV-2. *Viruses* **14**, 1–9 (2022).
- 307 7. Stakenborg, T. *et al.* Molecular detection of SARS-COV-2 in exhaled breath at the point-of-need.  
308 *Biosens. Bioelectron.* **217**, (2022).
- 309 8. Bos, D. A. G., Lagrou, K. & Verbakel, J. Y. Prospective Performance Evaluation of the  
310 miDiagnostics COVID-19 PCR Test for Rapid SARS-CoV-2 Detection on Nasopharyngeal Swabs.  
311 *J. Clin. Microbiol.* **61**, (2023).
- 312 9. Krijger, P. H. L. *et al.* A public–private partnership model for COVID-19 diagnostics. *Nat.*  
313 *Biotechnol.* **39**, 1182–1184 (2021).
- 314 10. InActiv Blue. DNA/RNA Defend Pro™ Universal buffer. (2023). Available at:  
315 <https://www.inactivblue.com/product-dna-rna-defend-pro/>. (Accessed: 15th August 2023)
- 316 11. RNAssist. VirusPHIX and VirusPHIX-P9. (2023). Available at: [https://rnassist.com/virusPHIX-](https://rnassist.com/virusPHIX-virus-transport-media/)  
317 [virus-transport-media/](https://rnassist.com/virusPHIX-virus-transport-media/). (Accessed: 19th September 2023)
- 318 12. Abbott. Abbott Panbio COVID-19 Ag Rapid Test Devices. (2023). Available at:  
319 [https://www.globalpointofcare.abbott/nl/nl/product-details/panbio-covid-19-ag-antigen-](https://www.globalpointofcare.abbott/nl/nl/product-details/panbio-covid-19-ag-antigen-test.html)  
320 [test.html](https://www.globalpointofcare.abbott/nl/nl/product-details/panbio-covid-19-ag-antigen-test.html). (Accessed: 1st August 2023)
- 321 13. Abbott. Alinity m resp-4-plex assay. (2023). Available at:  
322 <https://www.molecular.abbott/int/en/alinity-m-resp-4-plex-assay>. (Accessed: 2nd November  
323 2023)

324

325 Supplementary Data File 1

Sample	Rapid antigen test			Nucleic Acid Amplification Test						Delta Cq IAB- DRDP	Result NAAT SARS-CoV-2 DRDP reanalysis (Cq)	Interpretation NAAT DRDP reanalysis (Cq)	Result NAAT Influenza DRDP reanalysis (Cq)	Delta Cq DRDP - DRDP reanalysis	Delta Cq Influenza
	Result Diagnostic Panbio	Approximate left-over volume (µL)	Result DRDP	Result NAAT SARS-CoV-2 InActiv Blue (Cq)	Interpretation NAAT SARS-CoV-2 InActiv Blue (Cq)	Result NAAT Influenza (Cq)	Approximate dilution factor	Result NAAT SARS-CoV-2 DRDP (Cq)	Interpretation NAAT SARS-CoV-2 DRDP (Cq)						
1	Negative	50	Negative	N.A.	Negative		88	N.A.	Negative						
2	Negative (EPD)	100	Weak positive	21.65	Positive		44	24.81	Positive		3.16	25.20	Weak positive	0.39	
3	Negative	50	Negative	N.A.	Negative		88	N.A.	Negative						
4	No Data	75	Negative	N.A.	Negative		58	N.A.	Negative						2.28
5	No Data	55	Negative	N.A.	Negative	FluB 28.35	80	N.A.	Negative				FluB 30.63		
6	Negative	100	Negative	N.A.	Negative	FluA 14.24	44	N.A.	Negative				FluA 24.90		10.56
7	Positive	105	Positive	11.28	Very strong positive		42	16.06	Strong positive						
8	No Data	70	Negative	No Data	No Data		63	N.A.	Negative		4.78	16.53	Strong positive	0.47	
9	Negative	100	Negative	N.A.	Negative	FluA 26.45	44	N.A.	Negative				FluA 28.75		2.30
10	Negative	150	Negative	N.A.	Negative		29	N.A.	Negative						
11	Negative	75	Negative	N.A.	Negative		58	N.A.	Negative						
12	Negative	75	Negative	N.A.	Negative		58	N.A.	Negative						
13	No Data	160	Negative	N.A.	Negative	FluA 31.16	27	N.A.	Negative				FluA 36.41		5.25
14	No Data	200	Weak positive	12.59	Strong positive		22	33.23	Weak positive		20.64	33.90	Weak positive	0.67	
15	Negative	120	Negative	N.A.	Negative	FluA 14.72	36	N.A.	Negative				FluA 29.80		15.08
16	Negative	120	Negative	N.A.	Negative		36	N.A.	Negative						
17	Positive	130	Positive	N.A.	Negative		34	38.26	Weak positive						
18	Negative (no LIS data)	50	Negative	23.31	Positive		88	26.59	Weak positive		3.28	No reanalysis	No reanalysis		
19	No Data	60	Negative	N.A.	Negative		73	N.A.	Negative						
20	No Data	70	Negative	N.A.	Negative		63	N.A.	Negative						
21	No Data	50	Negative	N.A.	Negative		88	N.A.	Negative						
22	Negative	70	Negative	N.A.	Negative		63	N.A.	Negative						
23	Negative	70	Negative	N.A.	Negative		63	N.A.	Negative						
24	Negative	200	Negative	N.A.	Negative		22	N.A.	Negative						
25	No Data	50	Negative	N.A.	Negative	FluA 20.32	88	N.A.	Negative				FluA 22.72		2.40
26	Negative	100	Negative	N.A.	Negative		44	N.A.	Negative						
27	No Data	40	Negative	N.A.	Negative		109	N.A.	Negative						
28	Negative	50	Negative	N.A.	Negative		88	N.A.	Negative						
29	Positive	90	Positive	13.37	Strong positive		49	14.70	Strong positive		1.33	No reanalysis			
30	Positive	100	Positive	12.99	Strong positive		44	18.61	Positive		5.62	No reanalysis			
31	Positive	100	Positive	No Data	No Data		44	21.95	Positive						
32	Negative	50	Negative	N.A.	Negative		105	37.47	Weak positive			36.18	Weak positive	-1.29	
33	Positive	120	Positive	No Data	No Data		44	20.70	Positive			21.08	Positive	0.38	
34	Negative	150	Negative	17.69	Strong positive		29	N.A.	Negative						
35	No Data	50	Negative	N.A.	Negative		88	N.A.	Negative						
36	Positive	50	Positive	15.89	Strong positive		105	17.44	Strong positive		1.55	18.26	Strong positive	0.82	
	median	75					SARS-CoV-2			median Delta Cq	3.28				0.43
	range	40 - 200					Influenza A			mean Delta Cq	5.77				0.24
							Influenza B								
							58								

326